Incretins Are Reshaping Cardiovascular Outcomes in Diabetes and Obesity | Research

The takeaway

A comprehensive review details how incretin-based therapies, especially GLP-1 RAs, are fundamentally changing cardiovascular trajectories for diabetes and obesity patients.

Cardiovascular trajectory change
Incretins reducing major cardiovascular events in diabetes and obesity

What the researchers found

Incretin-based therapies are fundamentally changing cardiovascular outcomes in diabetes and obesity through multiple protective mechanisms supported by strong clinical trial evidence.

Why it matters

Cardiovascular disease is the leading cause of death in diabetes and obesity. Incretins are among the first drug classes to meaningfully reduce this risk.

How the study worked

Comprehensive review consolidating cardiovascular evidence for incretin-based medications including preclinical mechanisms and clinical trial outcomes.

What this study cannot tell us

Review — selective in coverage; cardiovascular outcome data for newest multi-agonists is still accumulating.

How to read the evidence

Comprehensive review — synthesizes landmark cardiovascular outcome trial data.

When this study was published

Published 2026 in European Journal of Clinical Investigation.

The bigger picture

The incretin revolution is redefining diabetes treatment from glucose-centric to cardiovascular risk-reduction-centric, with implications for clinical guidelines and insurance coverage.

Questions still open

Will dual and triple agonists show even greater cardiovascular protection than GLP-1 RAs alone?
Should all diabetes patients receive incretin-based therapy regardless of cardiovascular risk level?

Common questions

How do incretin drugs protect the heart?

GLP-1 medications reduce inflammation, improve blood vessel function, lower blood pressure, reduce harmful cholesterol, and promote weight loss — all of which decrease cardiovascular risk.

Are incretin drugs better than older diabetes medications for the heart?

Yes — multiple large trials show GLP-1 RAs reduce heart attacks, strokes, and cardiovascular death, unlike most older diabetes drugs which primarily lower blood sugar without cardiovascular protection.

Read the original research

Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.

European journal of clinical investigation, 56(2), e70184

View on PubMed ↗Publisher’s paper ↗

Citation

Avogaro, Angelo. (2026). Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.. European journal of clinical investigation, 56(2), e70184. https://doi.org/10.1111/eci.70184